Brian Mooney

Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma

Brian Mooney, Xiaojie Chu, Gian Luca Negri, Michael M. Lizardo et autres

Osteosarcoma (OS) is the most common human primary bone cancer, primarily affecting children and young adults. While the survival rate of patients diagnosed with localized OS is ∼65%, this decreases to ∼20% for patients with metastatic disease, and recurrent disease remains largely …

ca, us (code pays fourni par la source)

Abstract A022: Uncovering CAR-T targets from the cholangiocarcinoma proteome

Gregg B. Morin, Scott Brown, Tracy S. Lee, Sandra E. Spencer et autres

Abstract Objective: The project is designed to identify pairs of proteins for CAR-T co-targeting immunotherapy for cholangiocarcinoma (CCA) based on expression of surface proteins in proteomic experiments. Introduction: Cholangiocarcinoma is a rare cancer of the bile duct, with a dismal prognosis. Standard …

ca (code pays fourni par la source)

Abstract A021: Surface and global proteome profiling identifies ROR2 and other surface proteins as actionable immunotherapy targets in osteosarcoma

Brian Mooney, Xiaojie Chu, Gian Luca Negri, Michael Lizardo et autres

Abstract Objective: Osteosarcoma (OS) is the most common primary bone cancer affecting children and young adults, with an incidence of roughly 4.4 per million in the United States. While the survival rate of patients diagnosed with localized OS is ∼65%, this decreases …

us, ca (code pays fourni par la source)

Introducing the Sinclair Nanopig™ model: Preliminary genomic, proteomic, and hepatic CYP450 characterization for (bio)pharmaceutical safety assessment

Yafei Chen, Nathan J. Bivens, Hongwei An, Brian Mooney et autres

ca, us (code pays fourni par la source)

Protocol for plasma membrane enrichment by ultracentrifugation for mass spectrometry of cell lines, xenografts, and patient tumors

Amber K Hamilton, Brian Mooney, Tina Glisovic‐Aplenc, Alexander B. Radaoui et autres

The success of immunotherapies hinges on identifying targetable cell surface proteins expressed in the cancer of interest. Here, we present a protocol for enriching plasma membrane proteins for mass spectrometry analysis using a density gradient ultracentrifugation approach. We describe steps for cell …

us, ca (code pays fourni par la source)

ImmunoTar—integrative prioritization of cell surface targets for cancer immunotherapy

Rawan Shraim, Brian Mooney, Karina L. Conkrite, Amber K Hamilton et autres

MOTIVATION: Cancer remains a leading cause of mortality globally. Recent improvements in survival have been facilitated by the development of targeted and less toxic immunotherapies, such as chimeric antigen receptor (CAR)-T cells and antibody-drug conjugates (ADCs). These therapies, effective in treating both …

us, ca (code pays fourni par la source)

Introducing the Sinclair Nanopig™ Model: Preliminary Genomic, Proteomic, and Hepatic Cyp450 Characterization for (Bio)Pharmaceutical Safety Assessment

Yafei Chen, Nathan J. Bivens, Hongwei An, Brian Mooney et autres

us (code pays fourni par la source)

IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy

Rawan Shraim, Brian Mooney, Karina L. Conkrite, Amber K. Weiner et autres

Cancer remains a leading cause of mortality globally. Recent improvements in survival have been facilitated by the development of less toxic immunotherapies; however, identifying targets for immunotherapies remains a challenge in the field. To address this challenge, we developed IMMUNOTAR, a computational …

us, ca (code pays fourni par la source)

Abstract 1090: GPC2 directed CAR T cells are efficacious against fusion-positive and fusion-negative rhabdomyosarcomas

Rawan Shraim, Patrick M. Schuerch, Anna Maria Giudice, Karina L. Conkrite et autres

Abstract Background: Rhabdomyosarcoma (RMS) is an aggressive pediatric solid tumor with poor survival and new targeted therapies are needed. Aims: Using an integrative proteogenomic quantitative approach, we sought to identify candidate immunotherapeutic targets then validate top targets in RMS preclinical models. Methods: …

us (code pays fourni par la source)

Supplementary Data S3 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Brian Mooney, Gian Luca Negri, Taras Shyp, Alberto Delaidelli et autres

Scoring schema to prioritize candidate immunotherapy targets.

Supplementary Figure S13 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Brian Mooney, Gian Luca Negri, Taras Shyp, Alberto Delaidelli et autres

ENPP1 immunofluorescence.

Supplementary Figure S6 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma

Brian Mooney, Gian Luca Negri, Taras Shyp, Alberto Delaidelli et autres

Expression of ATP11C, SLCO5A1, and STEAP2 in publicly available datasets.